Skip to main content

Table 5 Estimation of the hazard ratio for disease-specific survival

From: Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis

Study HR estimation Co-factors Analysis results
Herr [5] P value, event no. pT stage, pN stage, no. of LNs removed, no. of positive LNs Significant
Wiesner [20] HR, 95 % CI No. of LNs removed, no. of positive LNs Significant
Furukawa [21] HR, 95 % CI No. of positive LNs, laterality of positive LNs, adjuvant chemotherapy Significant
Guzzo [22] HR, 95 % CI Age, sex, diversion type, pT stage, adjuvant chemotherapy Not significant
May [24] HR, 95 % CI Age, sex, radical cystectomy time frame, pT stage, pN stage, tumor grade, concomitant carcinoma in situ, adjuvant chemotherapy, no. of LNs removed Significant
Jensen [25] HR, 95 % CI Age, sex, pT stage, pN stage, metastasis above the aortic bifurcation, extracapsular extension, volume dependent LN density, diameter of largest LN, volume of metastatic LNs Not significant
Morgan [26] HR, 95 % CI Age, Charlson comorbidity index, pT stage, tumor grade, no. of LNs removed, adjuvant chemotherapy, diversion type, year of surgery, surgeon volume, transfusion Significant
Kassouf [27] HR, 95 % CI Age, sex, tumor grade, pT stage, margin status, lymphovascular invasion, adjuvant chemotherapy, concomitant carcinoma in situ Significant
Masson-Lecomte [28] P value, event no. pT stage, extracapsular extension, adjuvant chemoethrapy Not significant
Kwon [30] HR, 95 % CI pT stage, pN stage, no. of positive LNs, adjuvant chemotherapy Not significant
  1. HR: hazard ratio, LN: lymph node, CI: confidence interval